Increased Risk of Herpes Zoster Infection in Patients with Celiac Disease 50 Years Old and Older.

Autor: Chatterjee A; Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA., Chittajallu V; Digestive Health Institute, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Ford A; Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA., Alchirazi KA; Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA., Nanah R; Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA., Mansoor E; Digestive Health Institute, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA., DeLozier S; Clinical Research Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Jansson-Knodell C; Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA., Rubio-Tapia A; Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA. RUBIOTA@ccf.org.
Jazyk: angličtina
Zdroj: Digestive diseases and sciences [Dig Dis Sci] 2024 Aug; Vol. 69 (8), pp. 2922-2926. Date of Electronic Publication: 2024 May 30.
DOI: 10.1007/s10620-024-08487-6
Abstrakt: Background: Celiac Disease (CD) is associated with increased susceptibility to certain bacterial and viral infections. Herpes zoster (HZ) is a viral infection that can be prevented by immunization. In the US, the vaccine is recommended for adults ≥ 50 or ≥ 19 with certain at-risk conditions, not including CD.
Aims: We aimed to determine if adult patients aged < 50 or ≥ 50 years with CD had a higher risk of developing HZ.
Methods: We designed a retrospective cohort study. CD was defined as patients with the ICD-10 code for CD and positive Celiac serology. Patients with negative serology and lacking CD ICD-10 codes served as controls. Patients who had HZ before CD diagnosis were excluded. We formed two sub-cohorts, those aged < 50 (cohort 1) and aged ≥ 50 years (cohort 2), and evaluated HZ infection at 10-year follow-up. To account for confounding variables, we performed 1:1 propensity score matching (PSM).
Results: Following PSM, cohort 1 had 6,826 CD patients, and cohort 2 had 5,337 CD patients and respective matched controls. After ten years of follow-up, in cohort 1, 62 CD patients developed HZ versus 57 controls, RR: 1.09 (CI: 0.76-1.56, p-value = 0.64). In cohort 2, 200 CD patients developed HZ versus 159 controls, RR: 1.2 (CI: 1.02-1.54, p-value = 0.03).
Conclusion: There was no significant difference in the likelihood of getting HZ in CD patients < 50, although CD patients ≥ 50 had a modestly increased risk. Our findings do not support routine early vaccination for HZ in CD, and the vaccine should be offered at age 50.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: